抗PD-1检查点抑制剂治疗肢端黑色素瘤:193例日本患者的多中心研究
该多中心回顾性研究纳入21家日本机构2014–2018年接受抗PD-1抗体治疗的不可切除III/IV期肢端黑色素瘤患者193例,总体客观缓解率16.6%,中位总生存18.1个月;基线LDH正常者总生存显著优于异常者;甲下黑色素瘤较掌跖黑色素瘤缓解率更低、生存更差。
要点
- 抗PD-1抗体在晚期肢端黑色素瘤中疗效有限,总体ORR为16.6%。
- 基线LDH正常者中位OS显著优于异常者(24.9 vs 10.7个月,P<0.001)。
- 甲下黑色素瘤ORR和OS均显著劣于掌跖黑色素瘤,应考虑新型联合治疗研究。
核心结论
- 抗PD-1抗体在肢端黑色素瘤患者中疗效有限。
- 甲下黑色素瘤患者缓解率和生存更差,是免疫检查点抑制剂新型联合治疗研究的重点候选人群。
研究设计与样本
- 多中心回顾性研究,纳入21家日本机构2014–2018年接受抗PD-1抗体治疗的不可切除III期或IV期肢端黑色素瘤患者193例。
- 抗PD-1抗体作为一线治疗者143例(74.1%)。
- 基线LDH正常者102例(52.8%)。
主要发现
- 全部患者ORR为16.6%(完全缓解3.1%,部分缓解13.5%),中位OS为18.1个月。
- 基线LDH正常者中位OS为24.9个月,异常者为10.7个月(P<0.001)。
- 甲下黑色素瘤组ORR为8.6%(6/70),掌跖组为21.1%(26/123),P=0.026。
- 甲下黑色素瘤组中位OS为12.8个月,掌跖组为22.3个月,P=0.03。
临床怎么用
- 对于晚期肢端黑色素瘤,抗PD-1单药治疗获益有限,临床决策需结合甲下/掌跖亚型和基线LDH水平评估预后。
- 甲下黑色素瘤患者应答和生存较差,应优先考虑纳入免疫检查点抑制剂联合治疗的临床研究。
局限性
- 回顾性研究设计。
- 研究人群仅限日本患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acral melanoma (AM) is an epidemiologically and molecularly distinct entity that is underrepresented in clinical trials on immunotherapy in melanoma. We aimed to analyze the efficacy of anti-programmed cell death 1 (anti-PD-1) antibodies in advanced AM. PATIENTS AND METHODS: We retrospectively evaluated unresectable stage III or stage IV AM patients treated with an anti-PD-1 antibody in any line at 21 Japanese institutions between 2014 and 2018. The clinicobiologic characteristics, objective response rate (ORR, RECIST), survival estimated using Kaplan-Meier analysis, and toxicity (Common Terminology Criteria for Adverse Events 4.0.) were analyzed to estimate the efficacy of the anti-PD-1 antibodies. RESULTS: In total, 193 patients (nail apparatus, 70; palm and sole, 123) were included in the study. Anti-PD-1 antibody was used as first-line therapy in 143 patients (74.1%). Baseline lactate dehydrogenase (LDH) was within the normal concentration in 102 patients (52.8%). The ORR of all patients was 16.6% (complete response, 3.1%; partial response, 13.5%), and the median overall survival (OS) was 18.1 months. Normal LDH concentrations showed a significantly stronger association with better OS than abnormal concentrations (median OS 24.9 versus 10.7 months; P < 0.001). Although baseline characteristics were similar between the nail apparatus and the palm and sole groups, ORR was significantly lower in the nail apparatus group [6/70 patients (8.6%) versus 26/123 patients (21.1%); P = 0.026]. Moreover, the median OS in this group was significantly poorer (12.8 versus 22.3 months; P = 0.03). CONCLUSIONS: Anti-PD-1 antibodies have limited efficacy in AM patients. Notably, patients with nail apparatus melanoma had poorer response and survival, making nail apparatus melanoma a strong candidate for further research on the efficacy of novel combination therapies with immune checkpoint inhibitors.
引用
- Nakamura Y, Namikawa K, Yoshino K, et al. Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients. Ann Oncol. 2020. PMID: 32522691. doi:10.1016/j.annonc.2020.05.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。